Cover up! Big Pharma HIDING psoriasis drug risks

If you’re one of the millions of Americans who struggle with plaque psoriasis, you know first-hand how uncomfortable those dry, itchy rashes can be.

And those scaly patches are so embarrassing, you can’t even THINK about wearing anything but long sleeves and pants.

But this gets worse.

Because you’re ALSO more likely to develop an inflammatory bowel disease (IBD) like ulcerative colitis or Crohn’s disease.

IBD hits 1 out of 10 women with psoriasis. And the odds are greater if you also have psoriatic arthritis.

Researchers have spent DECADES trying to figure out the connection between these inflammatory conditions.

Yet the answer has been sitting right under their noses.

And one Pharma giant in particular is throwing a lot of money to make sure nobody figures out the REAL reason.

Cashing in on a cover-up

The form of psoriasis that forms those dry, scaly bumps – known as plaque psoriasis, the most common of the psoriatic diseases – is thought to be caused by an overactive immune reaction.

For whatever reason, your immune system initiates the growth of too many skin cells on the surface of certain parts of your body.

And like many autoimmune diseases, psoriasis is characterized by an overwhelming amount of inflammation in your body.

It shares that with IBD, another autoimmune disease.

But inflammation isn’t contagious. You can’t just “catch” IBD if you’ve already got psoriasis.

Researchers have taken a deep dive into the possible genetic link between these conditions.

Yet we already know that only a fraction of folks with a genetic predisposition to autoimmune diseases like these actually develop them.

There’s got to be a trigger.

And if your doc considers your plaque psoriasis severe enough to warrant taking a prescription drug, he may be pulling the trigger on IBD.

You see, unlike topical creams and ointments, drugs that treat psoriasis are considered “systemic.”

That is, they work throughout your body.

And the #1 way they attack psoriasis is by throwing a wet blanket on your overactive immune reaction.

But monkeying around with your immune system isn’t without its own risks.

In the case of the injectable psoriasis drug ixekizumab (a.k.a. Taltz), it inhibits a pro-inflammatory cytokine called interleukin 17A (IL-17A). IL-17 is a substance secreted by certain immune cells known as T helper cells.

Cytokines occur naturally in our bodies and are an essential component of our normal immune responses.

You can’t just cut off the supply of it at the source without it impacting some other system in your body.

Of course, the maker of Taltz, Eli Lilly and Company, continues to fund studies that find the concurrence of the two diseases to be “uncommon.”

Yet the incidences and exacerbations of IBD were common enough in the drug’s original clinical trials for the drugmaker to urge docs to monitor their patients “closely” if they’re on Taltz.

If you didn’t have IBD before, symptoms can emerge within the first three months of being injected with Taltz.

So, even if it clears your maddening skin condition, you’re instead saddled with abdominal paindiarrhea… and even bloody stool.

Yikes!

Don’t make a trade-off like that. It’s nothing but a bad deal.

Phototherapy has worked wonders for psoriasis sufferers… and won’t cause ANY digestive issues.

Topical herbal therapies like aloe vera, capsaicin, and licorice root can also provide some relief.

See a doctor skilled in nutritional medicine about oral supplements you can take, like B vitamins and essential elements.

They typically work within three months – just as quickly as the bad-news injection that Big Pharma SWEARS is safe!